Hira Mian, MD, McMaster University, Hamilton, Ontario, gives an overview of the IINNOVATE clinical trials, which are exploring the safety and efficacy of modakafusp alfa as a monotherapy and in combination with other agents for the treatment of patients with relapsed/refractory (R/R) multiple myeloma (NCT03215030; NCT05556616; NCT05590377). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.